Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T, Shoji B, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Yamamoto K. Nishida T, et al. Among authors: kobashi h. J Gastroenterol Hepatol. 2008 May;23(5):794-803. doi: 10.1111/j.1440-1746.2007.05240.x. Epub 2007 Dec 14. J Gastroenterol Hepatol. 2008. PMID: 18086120 Clinical Trial.
Lamivudine treatment improves the prognosis of fulminant hepatitis B.
Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, Kobashi H, Sakaguchi K, Shiratori Y. Miyake Y, et al. Among authors: kobashi h. Intern Med. 2008;47(14):1293-9. doi: 10.2169/internalmedicine.47.1061. Epub 2008 Jul 15. Intern Med. 2008. PMID: 18628576 Free article.
Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.
Iwasaki Y, Tanaka H, Ikeada H, Okamoto R, Araki Y, Yabushita K, Kobashi H, Kariyama K, Kawaguchi M, Takaguchi K, Sakata T, Ando M, Sakaguchi K, Aoki N, Shiratori Y. Iwasaki Y, et al. Among authors: kobashi h. Scand J Gastroenterol. 2011 Jan;46(1):79-90. doi: 10.3109/00365521.2010.516449. Epub 2010 Sep 7. Scand J Gastroenterol. 2011. PMID: 20822376
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Ikeda F, et al. Among authors: kobashi h. J Med Virol. 2012 Oct;84(10):1562-70. doi: 10.1002/jmv.23371. J Med Virol. 2012. PMID: 22930504
Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, Kobashi H, Kobatake T, Tanaka R, Tomita M, Senoh T, Kawaguchi M, Shimoe T, Manabe K, Kita K, Shimamura J, Sakaguchi K, Shiratori Y. Iwasaki Y, et al. Among authors: kobashi h. Liver Int. 2004 Dec;24(6):603-10. doi: 10.1111/j.1478-3231.2004.0956.x. Liver Int. 2004. PMID: 15566511
225 results